FFO
FDMT icon

Fortitude Family Office’s 4D Molecular Therapeutics FDMT Stock Holding History

Fortitude Family Office’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78K Buy
134
+78
+139% +$760 ﹤0.01% 1523
2026
Q1 		$521 Buy
+56
New +$487 ﹤0.01% 1713

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Fortitude Family Office's FDMT Position: Q2 2026 in Review

Fortitude Family Office increased its 4D Molecular Therapeutics (FDMT) stake by 139% in Q2 2026, buying an estimated $760 and bringing the position to 134 shares worth $1.78K. The position accounts for ﹤0.01% of the portfolio, ranked #1523.

Fortitude Family Office first reported a position in FDMT in Q1 2026 and has held it in 2 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Fortitude Family Office held 134 shares of 4D Molecular Therapeutics worth $1.78K as of Q2 2026.
  • Fortitude Family Office bought 78 4D Molecular Therapeutics shares in Q2 2026, an estimated $760.
  • 4D Molecular Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1523 holding.
  • Fortitude Family Office first reported a position in 4D Molecular Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.